Calcium Antagonists. Mechanisms, Therapeutic Indications and Reservations: A Review
Identifieur interne : 002A36 ( Main/Exploration ); précédent : 002A35; suivant : 002A37Calcium Antagonists. Mechanisms, Therapeutic Indications and Reservations: A Review
Auteurs : Lionel H. Opie [Afrique du Sud]Source :
- QJM: An International Journal of Medicine [ 1460-2725 ] ; 1984.
Abstract
SUMMARY The chief site of action of the calcium antagonist drugs is the slow calcium channel in two tissues: the atrioventricular node and vascular smooth muscle. The exact mode whereby these agents work is still unknown, but recently studies withradioligands suggest that the binding site for the dihydropyridines such as nifedipine is different from the site for theverapamil group (including diltiazem). In some way these agents ‘close’ or ‘block’ the calcium channels. Verapamil and diltiazem are active against the calcium channel of the atrioventricular node which nifedipine in clinical doses is not; in contrast, nifedipine is more active on peripheral vascular arterial muscle, presumably inhibiting the calcium channel more strongly. An intracellular site of action of these agents on calmodulin in vascular smooth muscle cannot be excluded. Clinically, the chief calcium antagonists (verapamil, nifedipine, diltiazem) constitute a powerful group of cardioactive agents with a spectrum of therapeutic actions rather similar to beta-adrenoceptor blockade, beingeffective in angina of effort and rest, and hypertension. Critical differences are dependent on the individual propertiesof the calcium antagonists. Thus only verapamil and diltiazem are effective in inhibiting the AV node while the dihydropyridines such as nifedipine are only vasodilators in clinical doses. As a group, calcium antagonists cause vascular dilation and do not cause bronchial constriction, in contrast to the beta-adrenoceptor blocking agents. In many patients these diverse properties allow safe combination of calcium antagonists and beta-adrenoceptor blockers if due care is observed.
Url:
DOI: 10.1093/oxfordjournals.qjmed.a067780
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Calcium Antagonists. Mechanisms, Therapeutic Indications and Reservations: A Review</title><author wicri:is="90%"><name sortKey="Opie, Lionel H" sort="Opie, Lionel H" uniqKey="Opie L" first="Lionel H." last="Opie">Lionel H. Opie</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9A04EF26754681673DAB22176D9CA6DD4D55CB3B</idno><date when="1984" year="1984">1984</date><idno type="doi">10.1093/oxfordjournals.qjmed.a067780</idno><idno type="url">https://api.istex.fr/document/9A04EF26754681673DAB22176D9CA6DD4D55CB3B/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">003084</idno><idno type="wicri:Area/Main/Curation">002C89</idno><idno type="wicri:Area/Main/Exploration">002A36</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Calcium Antagonists. Mechanisms, Therapeutic Indications and Reservations: A Review</title><author wicri:is="90%"><name sortKey="Opie, Lionel H" sort="Opie, Lionel H" uniqKey="Opie L" first="Lionel H." last="Opie">Lionel H. Opie</name><affiliation wicri:level="1"><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>MRC-UCT Ischaemic Heart Disease Research Unit, Department of Medicine, Groote Schuur Hospital and University of Cape Town</wicri:regionArea><wicri:noRegion>Groote Schuur Hospital and University of Cape Town</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">QJM: An International Journal of Medicine</title><idno type="ISSN">1460-2725</idno><idno type="eISSN">1460-2393</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="1984">1984</date><biblScope unit="volume">53</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="1">1</biblScope><biblScope unit="page" to="16">16</biblScope></imprint><idno type="ISSN">1460-2725</idno></series><idno type="istex">9A04EF26754681673DAB22176D9CA6DD4D55CB3B</idno><idno type="DOI">10.1093/oxfordjournals.qjmed.a067780</idno><idno type="ArticleID">53.1.1</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1460-2725</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">SUMMARY The chief site of action of the calcium antagonist drugs is the slow calcium channel in two tissues: the atrioventricular node and vascular smooth muscle. The exact mode whereby these agents work is still unknown, but recently studies withradioligands suggest that the binding site for the dihydropyridines such as nifedipine is different from the site for theverapamil group (including diltiazem). In some way these agents ‘close’ or ‘block’ the calcium channels. Verapamil and diltiazem are active against the calcium channel of the atrioventricular node which nifedipine in clinical doses is not; in contrast, nifedipine is more active on peripheral vascular arterial muscle, presumably inhibiting the calcium channel more strongly. An intracellular site of action of these agents on calmodulin in vascular smooth muscle cannot be excluded. Clinically, the chief calcium antagonists (verapamil, nifedipine, diltiazem) constitute a powerful group of cardioactive agents with a spectrum of therapeutic actions rather similar to beta-adrenoceptor blockade, beingeffective in angina of effort and rest, and hypertension. Critical differences are dependent on the individual propertiesof the calcium antagonists. Thus only verapamil and diltiazem are effective in inhibiting the AV node while the dihydropyridines such as nifedipine are only vasodilators in clinical doses. As a group, calcium antagonists cause vascular dilation and do not cause bronchial constriction, in contrast to the beta-adrenoceptor blocking agents. In many patients these diverse properties allow safe combination of calcium antagonists and beta-adrenoceptor blockers if due care is observed.</div></front></TEI><affiliations><list><country><li>Afrique du Sud</li></country></list><tree><country name="Afrique du Sud"><noRegion><name sortKey="Opie, Lionel H" sort="Opie, Lionel H" uniqKey="Opie L" first="Lionel H." last="Opie">Lionel H. Opie</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A36 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002A36 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9A04EF26754681673DAB22176D9CA6DD4D55CB3B
|texte= Calcium Antagonists. Mechanisms, Therapeutic Indications and Reservations: A Review
}}
| This area was generated with Dilib version V0.6.23. |  |